Zorevunersen demonstrates disease-modifying potential in patients with Dravet syndrome with improvements in seizure burden, quality of life, and overall clinical status

Topic: Dravet Syndrome Presentations

Zorevunersen demonstrates disease-modifying potential in patients with Dravet syndrome with improvements in seizure burden, quality of life, and overall clinical status

EEC 2026

September 3, 2026

View Presentation

Zorevunersen demonstrates potential as a disease‑modifying therapy in patients with Dravet syndrome: A matching-adjusted indirect comparison between natural history and patients receiving zorevunersen

EEC 2026

September 3, 2026

View Poster

Zorevunersen demonstrates potential as a disease‑modifying therapy in patients with Dravet syndrome through durable seizure reduction and improvements in cognition, behaviour, and quality of life through 48 months of treatment in open‐label extension studies​

EEC 2026

September 3, 2026

View Poster

Electrophysiological improvements in patients with Dravet syndrome following treatment with zorevunersen, an investigational antisense oligonucleotide

AAN 2026

April 20, 2026

View Presentation

Zorevunersen demonstrates potential as a diseasemodifying therapy in patients with Dravet syndrome through durable seizure reduction and improvements in cognition, behavior, and quality of life through 36 months of treatment in open-label extension studies

AAN 2026

April 20, 2026

View Presentation

Zorevunersen in Children and Adolescents with Dravet Syndrome

The New England Journal of Medicine

March 5, 2026

View Article

Zorevunersen continues to demonstrate potential as a disease-modifying therapy in long-term open-label extension studies of patients with Dravet syndrome​

AES 2025

December 5, 2025

View Presentation

Zorevunersen continues to demonstrate potential as a disease-modifying therapy in long-term open-label extension studies of patients with Dravet syndrome

AES 2025

December 5, 2025

View Poster

Zorevunersen demonstrates disease-modifying potential in patients with Dravet syndrome with increases in seizure-free days, improvements in quality of life, and benefits in overall clinical status

AES 2025

December 5, 2025

View Poster

Spectral electroencephalogram abnormalities across development in patients with Dravet syndrome

AES 2025

December 5, 2025

View Poster
Next Page